SAN CARLOS, Calif., October 23, 2022 (GLOBE NEWSWIRE) — Vaxcyte, Inc. PCVXan innovative clinical-stage vaccines company developing high-fidelity vaccines to protect humanity from the consequences of bacterial diseases, announced today that it will launch tomorrow, October 24, 2022 at 8:00 a.m. Eastern Time will hold a webcast and conference call to provide Topline with results from its Phase 1/2 proof of concept study evaluating the safety, tolerability and immunogenicity of VAX-24, the investigational 24-valent pneumococcal conjugate vaccine (PCV) of the company, in healthy adults aged 18 to 64 years.
Those wishing to participate can access the live webcast hereor pre-register for the conference call here. A live webcast of the conference call will also be available on the Investor Relations page of Vaxcyte’s corporate website at www.vaxcyte.com. After the live webcast, the event will be archived on the Vaxcyte website for 30 days.
About Vacyte
Vaxcyte is an innovative vaccine company developing high-fidelity vaccines to protect humanity from the consequences of bacterial diseases. The company develops broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a broad-spectrum, 24-valent pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is reimagining the way highly complex vaccines are made using modern synthesis techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Manufacturing difficult-to-make proteins and antigens is expected to accelerate the company’s ability to efficiently manufacture and deliver highly accurate vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-XP, a PCV with expanded coverage of more than 30 strains; VAX-A1, a…
